Exchange Traded Concepts LLC Grows Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Exchange Traded Concepts LLC boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 6.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 319,682 shares of the company's stock after acquiring an additional 20,031 shares during the period. Exchange Traded Concepts LLC owned about 0.69% of Omnicell worth $14,232,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after buying an additional 553 shares during the last quarter. 1620 Investment Advisors Inc. boosted its position in shares of Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after acquiring an additional 1,542 shares in the last quarter. Summit Global Investments purchased a new position in shares of Omnicell in the 3rd quarter valued at about $221,000. QRG Capital Management Inc. acquired a new stake in shares of Omnicell during the 3rd quarter worth about $231,000. Finally, Everence Capital Management Inc. acquired a new position in Omnicell in the third quarter valued at approximately $249,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Price Performance

Shares of NASDAQ:OMCL traded up $0.46 on Friday, reaching $43.63. The company's stock had a trading volume of 231,033 shares, compared to its average volume of 328,116. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The stock's 50-day moving average is $44.65 and its two-hundred day moving average is $42.02. The stock has a market capitalization of $2.02 billion, a P/E ratio of -111.87, a PEG ratio of 29.73 and a beta of 0.78.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Craig Hallum upped their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Bank of America cut their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Finally, Benchmark reissued a "buy" rating and issued a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of "Hold" and a consensus target price of $50.00.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now owns 58,427 shares of the company's stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.64% of the company's stock.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.